389 results about "Overweight" patented technology

An apparatus and method are disclosed for treating overweight and obese patients by applying a restrictive Artificial Gastric Valve (AGV) on part of the stomach. The apparatus includes a mechanism to control the opening of the AGV automatically on demand, dynamically and progressively. The controlled opening of the AGV inside the stomach controls and regulates the flow of food.

A gastric balloon apparatus. An apparatus is disclosed that is insertable into a patent's stomach for treatment of overweight. The balloon occupies a volume of the gastric lumen to provide a sensation of fullness after the consumption of only modest amounts of food. The balloon apparatus has a basic toroidal shape to prevent blockage of the entrance or exit lumens of the stomach and promote proper passage of food through the stomach, while protecting the stomach lining from ulceration and irritation. A series of toroidal balloons of graduated diameter may be joined by inner and outer sleeves to define a funnel-shaped apparatus which expands when food is ingested, thus satiating the patient with substantially reduced quantity of food. A balloon storage and insertion apparatus also is disclosed, whereby a gastric balloon according to the disclosure may be pre-inflated and stored ion a tube for later use, whereupon the pre-inflated balloon is deployed into the stomach. Various mechanisms are disclosed for providing a pre-determined deflation of an inserted balloon, permitting the deflated balloon to be excreted from the body.

An endoscopically implantable device is provided that cinches the stomach together to create a reduced diameter for a portion of the stomach. The device may be, for example, a gastrorestrictive device used to treat overweight or obese patients. The device may be used, for example, to treat gastroesophogeal reflux disease (GERD).

A user portable measurement device (100) includes a measurement unit (174) for measuring and monitoring human health information, a user interface (175) for presenting information based on a measurement result, elements for storing information relating to the care of the user (173), and elements for forming activity instructions on the basis of the care information and at least one measurement result. The user interface (175) of the measurement device (100) preferably includes a display for presenting characters and / or symbols and elements for forming a tone and / or speech. The device is especially suitable for e.g. monitoring and care of overweight and diabetes. A system having many user devices and a server for acquisition and storage of the measurement data is also described. The server may further be used to provide an access to game or chat program services to motivate or help individual users of the measurement devices.

The present invention relates to a method for the treatment and / or prevention of overweight in a monogastric mammal. More particularly, the invention is concerned with such a method comprising administering to the mammal a liquid edible composition with a pH of more than 5, a viscosity below 50 mPas at a shear rate of 100 s-1 and 20° C., and a viscosity of at least 125% of the aforementioned viscosity at a pH 3 and a temperature of 37° C.; and with a caloric density between 0 and 500 kcal per liter, the composition comprising: c. between 0.01 and 5 wt. % of one or more polysaccharides selected from the group consisting of pectin and alginate; and between 0.01 and 3 wt. % calcium

Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and / or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.

The present invention relates to a method of treating or preventing obesity, overweight, fluctuations in blood insulin levels and / or fluctuations in blood glucose levels in mammals. The method acording to the invention comprises the enteral administration to a mammal of an effective amount of a preparation containing an enzyme capable of converting an ingested carbohydrate or digestion product thereof into one or more absorbable components, wherein the total metabolic caloric value of the absorbable component(s) is less than the metabolic caloric value of the ingested carbohydrate or digestion product thereof. Thus the present invention effectively provides a method that allows complete digestion of ingested digestible carbohydrates whilst at the same time reducing the actual metabolic caloric value of said ingested carbohydrates. Another aspect of the invention relates to a pill for oral administration provided with an enteric coating and containing 25 to 10.000 IU glucose isomerase per gram.

Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and / or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.

The present invention provides methods of treating or preventing disorders or conditions associated with an undesirable level of a satiety factor by administering to a subject in need thereof an effective amount of an agonist or antagonist of a satiety factor. The present invention also provides methods of selecting a subject for therapy with an agonist or antagonist of a satiety factor. Exemplary disorders or conditions associated with an undesirable level of a satiety factor include overweight, obesity, metabolic disorders, hypertension, lipid related disorders, anorexia and type II diabetes.

The invention relates to melanocortin receptor-specific cyclic peptides of Formula (I)or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4a, R4b, R4c, R5, x and y are as defined in the specification. These compounds are particularly useful in the treatments of energy homeostasis and metabolism related (e.g. diabetes), food intake related and / or energy balance and body weight related diseases, disorders and / or conditions, including obesity, overweight and diseases, disorders and / or conditions associated with obesity and / or overweight, such as type 2 diabetes and metabolic syndrome.

One aspect of the present invention relates to a liquid edible composition with a pH of more than 6, a viscosity below 600 mPas at a shear rate of 100s−1 and 20° C., and a viscosity of at least 125% of the aforementioned viscosity at a pH below 5 and a temperature of 37° C., the composition comprising at least 0.05 wt. % of pectin having a degree of methoxylation between 2 and 50 and / or of alginate; at least 5 mg calcium per 100 ml; and at least 0.1 wt. % indigestible oligosaccharide having a degree of polymerisation between 2 and 60.Another aspect of the invention relates to a method for the treatment or prevention of overweight or obesity in mammals, said method comprising the enteral administration to a mammal of an effective amount of the aforementioned composition.

A treatment for obesity and overweight comprises administering a vitamin D analog. The analog effectively inhibits an increase in body fat to animals at risk and decreases the basal fat content of animals. The treatment has a positive effect on the lean body component such that while there is an overall decrease in body weight, there is also a decrease in percent body fat. This decrease can be proportionally greater than the overall decrease in body weight. In addition, the treatment has a positive effect on bone turnover and osteogenesis making the vitamin D analog a beneficial treatment for the symptoms of menopause. Various exemplary embodiments of the treatment use the 2-alkylidene derivatives of vitamin D3, such as the 2-alkylidene-19-nor derivatives in both the R and S configurations at carbon-20.

The invention relates to a composite with weight-reducing, body-shaping and weight-controlling functions. The composite comprises, by weight, 30%-80% of water-soluble dietary fibers, 5%-60% of white kidney bean extract, 5%-50% of oligosaccharide powder and 1%-20% of haw apple extract. The composite has effects for fat people or overweight but not fat people, and can effectively reduce the weight, lower the fat percentage, facilitate reduction of body fat, obviously reduce the waistlines and the hipline, strengthen muscle, improve the body shape, enable the body to be more curvaceous, and be used for weight control. The composite further has an auxiliary function for hyperglycemia and hyperlipidemia people. In addition, the composite can regulate intestinal flora, improve the breeding environment for beneficial bacteria of the intestinal tract of the human body, promote excretion of vivotoxin and metabolic waste, and achieve the effects of expelling of noxious substances and beauty. The composite is convenient to take, meets the requirement for a rapid pace of life for modern people, and is safe, effective and free of any toxic and side effect.

A nutritional supplement composition having therapeutically effective amounts of milk minerals including calcium, a protein source including κ-casein fragment 106-169, and enzyme-inhibiting peptides is provided for the treatment of body weight conditions. The nutritional supplement composition is administered in amounts effective for limiting weight gain and / or enhancing weight loss, as well as promoting overall good health, in the treatment of body weight conditions, including overweight and obesity.

A treatment for obesity and overweight comprises administering a vitamin D analog. The analog effectively inhibits an increase in body fat to animals at risk and decreases the basal fat content of animals. The treatment has a positive effect on the lean body component such that while there is an overall decrease in body weight, there is also a decrease in percent body fat. This decrease can be proportionally greater than the overall decrease in body weight. In addition, the treatment has a positive effect on bone turnover and osteogenesis making the vitamin D analog a beneficial treatment for the symptoms of menopause. Various exemplary embodiments of the treatment use the 2-alkylidene derivatives of vitamin D3, such as the 2-alkylidene-19-nor derivatives in both the R and S configurations at carbon-20.

The invention discloses a reinforcement method and a reinforcement structure for treating railway soft soil roadbed settlement overweight before operation. The reinforcement structure mainly consists of five parts, namely a main bearing structure system, a reinforced cushion layer structure system, a foundation bed drainage system, a settlement observation system and a reserved grouting system. The technical problems that the existing roadbed is greatly damaged, the construction period is long, the construction property is low, the quality is difficult to control and the problem that the soft soil roadbed settlement overweight is caused in the conventional technical scheme are effectively solved.

The invention pertains to a composition and a method for the treatment of mood disorders, in particular of treating, preventing or alleviate depression, mood disorders or insufficient mood, obesity, overweight, premenstrual syndrome, craving, carbohydrate craving, chocolate craving, menopausal complaints, erectile dysfunction and / or reduced libido. The composition contains cocoa or one or more of its pharmacologically active components, and a dopamine D2 receptor agonist.

Provided are methods for reducing food consumption, and methods for altering behavioral, neurological, psychological, or physiological responses to a food portion, mainly for use by an obese or overweight user, or by a user at risk of weight gain. Also provided are user-interactive systems and apparatuses for employing such methods.

The invention discloses an integral lifting reconstruction method for a high-span overweight continuous box girder. The method comprises the following steps of: cutting the top of a pier; reinforcing an upper box girder; welding a limiting device on the outer side of an upright post hoop, and integrating the limiting structure and a concrete pier into a whole to limit the lifting of the girder; debugging a lifting jack and a follow-up jack; lifting formally until the girder is lifted to a position which is 1cm higher than a designed elevation, screwing up a self-threaded device of the lifting jack, disassembling the follow-up jack, arranging a support and a permanent cushion block; loosening the self-threaded device on the lifting jack and allowing the jack to drop for 1 cm to the designed elevation; and disassembling the lifting device, the hoop and the limiting device and joining the lifted pier. The method can adapt to the high-span continuous box girder with limited height at the support, heavy weight, high requirements on a lifting hydraulic device and small width at the ribbed part of the box girder and can realize safe integral lifting of the continuous box girder with an accurate position.

The present invention relates to methods of managing weight, and treating overweight or obesity and treating or preventing diabetes in a subject in need thereof. In one embodiment, the method comprises the steps of (a) orally administering to the subject from about 0.7 g to about 4 g of crosslinked carboxymethylcellulose; and (b) orally administering to the subject at least about 100 mL of water per gram of crosslinked carboxymethylcellulose. Steps (a) and (b) are conducted prior to or with at least one meal per day.

The invention provides a Gongtai special mixed feed for late pregnancy of pregnant sows and a preparation method thereof. The feed of the invention comprises the following raw materials (by weight): 30-40 parts of corn, 20-25 parts of wheat bran, 10-20 parts of soybean meal, 0-10 parts of vinasse protein, 0-10 parts of rice bran meal, 0-2.5 parts of soybean oil, 0-1 part of white sugar, 1-1.3 parts of fine ground limestone, 0.5-1 part of calcium hydrogen phosphate, 0.3-0.4 part of salt, 0.2-0.3 part of an acidifier, 0-0.15 part of choline chloride, 0-0.08 part of L-lysine, 0-0.06 part of DL-methionine, 0-0.06 part of threonine, 0-0.1 part of sodium butyrate, 0-0.12 part of a mildew inhibitor, 0-0.1 part of Novasil, 0-0.02 part of a flavouring agent, 0.5-1.5 parts of a vitamin premix and 0.5-1.5 parts of a microelement premix. Based on the newest sows nutrition theory and by combination of production reality, feed energy, protein level, vitamin, mineral elements, dietary fiber and other ingredients are designed reasonably, and problems such as sow body overweight, fetal oversize, prolonged labor, constipation and the like which are caused by existing lactation feeds for Gongtai are overcome.

The invention relates to Bifidobacterium CECT 7765 and to the use thereof in the prevention and / or treatment of overweight, obesity and related pathologies. The invention likewise relates to the Bifidobacterium CECT7765 strain, to the cellular components, metabolites and secreted molecules thereof, to the combinations thereof with other microorganisms, and to compositions that include the preceding products, as well as to the use of one strain of the species Bifidobacterium pseudocatenulatumo and to the use of the CECT 7765 strain for preventing and / or treating obesity; excess weight; hyperglycemia; and diabetes, preferably type-2 Diabetes Mellitus; hepatic steatosis or fatty liver; dyslipidemia; metabolic syndrome; immune system dysfunction associated with obesity and excess weight; and an imbalance in the composition of the intestinal microbiota associated with obesity and excess weight.

The present invention relates to the Bifidobacterium CECT 7765 strain, to its cell components, metabolites, and secreted molecules, to the combinations thereof with other microorganisms, and to compositions comprising the aforementioned products, as well as to the use of a strain of the Bifidobacterium pseudocatenulatum species, or to using the CECT 7765 strain for the prevention and / or treatment of obesity, overweight, hyperglycemia and diabetes, preferably type 2 diabetes mellitus, hepatic steatosis or fatty liver, dyslipidemia, metabolic syndrome, immune system dysfunction associated with obesity and overweight; and an unbalanced composition of the intestinal microbiota associated with obesity and overweight.

An obesity preventing and tracking system, the system comprising: at least one in-building overweight and obesity preventing module for collecting anthropometry information from a person at a fixed location in order to forecast and prevent development of an obesity condition; and / or at least one on-board vehicle overweight and obesity preventing module for collecting the anthropometry information from the person in a vehicle operable by the person in order to forecast and prevent development of an obesity condition and / or at least one entertainment overweight and obesity preventing module for collecting anthropometry information from said person while said person is a guest at an entertainment facility in order to forecast and prevent development of an obesity condition; and a communications network for linking at least one in-building overweight and obesity preventing module and at least one on-board vehicle overweight and obesity preventing module and at least one entertainment overweight and obesity preventing module to a trend obesity preventing service for predicting the development of an obesity condition of the person.

The present invention relates to an edible foam product that can advantageously be used in the treatment or prevention of obesity. More particularly, the present invention provides an edible foam product of pourable or spoonable consistency having an overrun of at least 100%, said foam product containing at least 60 wt. % of water, from 1 to 7 wt. % of protein and from 1 to 20 wt. % of carbohydrates, and further being characterised by a high in-mouth stability as evidenced by a reduction in overrun of less than 35% under in-mouth shear conditions and a high gastric stability as evidenced by a t½>30 minutes, t 1 / 2 representing the time needed to achieve a reduction in overrun of 50% under gastric conditions. Another aspect of the invention relates to the use of an edible foam product in the treatment or prevention of overweight or obesity, said edible foam product having a pourable or spoonable consistency, an overrun of at least 100% and a high gastric stability as evidenced by t 1 / 2 >30 minutes. Yet another aspect of the invention concerns a pressurised container holding an edible liquid composition and a propellant, which liquid composition can be released from the container by activating a valve to produce an edible foam product having a pourable or spoonable consistency, an overrun of at least 100% and a high gastric stability as evidenced by t 1 / 2 >30 minutes.

The invention discloses a health-care food suitable for patient with type 2 diabetes mellitus, in particular to a health-care food suitable for overweight and obesity patient with type 2 diabetes mellitus. The health-care food is prepared by uniformly mixing the following raw materials in parts by weight: 20-120 parts of Avena nuda, 1-15 parts of Moringa leaf powder, 1-5 parts of yeast powder and 1-5 parts of wheat germ. The method for eating the health-care food is as follows: 400ml of water is added in 40g of health-care food, the mixture is boiled for 1-2 minutes, and subsidiary food is matched according to diabetes food management, wherein the health-care food as the main food is taken twice a day by 40g each time for 12 weeks. The health-care food has the advantages of low treatment cost and no toxic or side effect, is favorable for improving sugar, fat and uric acid metabolism and high INS (insulin secretion) septicemia of a patient, reversing fatty liver and controlling hypertension, and is also favorable for patients to insist in orally taking drug for lowering blood sugar, raw materials are abundant, the weight of overweight and obesity patient with type 2 diabetes mellitus can be lowered.

The invention provides a traditional Chinese medicine for treating metabolic syndrome and a preparation method thereof. The traditional Chinese medicine is prepared from eleven traditional Chinese medicines including codonopsis pilosula, Indian buead, cassia twig, bighead atractylodes rhizome, radix glycyrrhizae preparata, capillary wormwood, rhizoma pinellinae praeparata, rheum, rhizoma atractylodis, pearl barley and pericarpium citri reticulatae. The prescription sticks to pathological changes in the process of strictly controlling diets of patients with metabolic diseases, the medicines are reasonably compatible to have the effects of strengthening spleen, purging turbidity and warming phlegm-fluid retention. The traditional Chinese medicine is used for preventing and treating overweight / obesity and relative metabolic diseases, such as diabetes, hypertension, hyperlipidaemia, fatty liver diseases and the like. A preliminary clinical trial shows that the traditional Chinese medicine has the advantages of definite effect, quick action and no toxic or side effect, can greatly improve the capability of resisting hunger and the compliance for receiving diet control of the patients with metabolic syndrome, and is a good medicine for clinically treating metabolic syndrome.

The invention relates to a hanger capable of preventing overweight, comprising a hanger seat, a support rod, a support measuring device, an inclinator, a balancer, a cant hook, a casing (or a lever, or a lock, or a pull rod, or a line) and the like. The hanger is characterized in that the hanger seat is connected with the support rod, the support rod is connected with the inclinator and the support measuring device (or the lever, or the pull rod) and the like, the support measuring device is connected with the cant hook and the balancer ( or the lever, or the lock, or the inclinator) and the like, and the inclinator is connected with the lock ( or the lever, or the cant hook) and the like; and when a loaded object on the cant hook is greater than the regulated weight, the cant hook inclines immediately and separates from the loaded object for reset, thus the problem of frequent damage to traditional hangers due to overweight can be solved. The invention is a humanized living and working article.